|drug2807||Recombinant human angiotensin-converting enzyme 2 (rhACE2) Wiki||1.00|
|drug2416||Patch, Placebo Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
There is currently no known treatment for COVID19. Active smokers are infrequent among patients with COVID-19 which has led our team to hypothesize that nicotine is responsible for this protective effect via the nicotinic acetylcholine receptor (nAChR). In fact, nAChR possess the ability to modulate ACE2 expression, the cellular doorway for SARS-CoV2. nAChR modulation by the virus would be responsible for the numerous clinical signs observed in COVID-19, including the cytokine storm manifested in intensive care hyperinflammatory patients. Based on epidemiological data and experimental data from scientific literature, our team hypothesize that nicotine could inhibit the penetration and propagation of SARS-CoV2. Our team also claim that nicotine could attenuate the hyperinflammatory response and cytokine storm leading to acute respiratory failure and a probable multi-organ failure associated with COVID19.
Description: Without reintubation or death in the following 48 hours for tracheotomized patients: alive and not ventilated for 48 hours (with death and LATA in competitive risks).Measure: Time before successful extubation Time: Day 60
Description: This is a ranked composite score that incorporates death and days free from mechanical ventilation through day 28, calculated in such a manner that death constitutes a worse outcome than fewer days off the ventilator.16 Time free from mechanical ventilation was calculated as the number of days between successful liberation from the ventilator and study day 60. Each patient was compared with every other patient in the study and assigned a score (tie: 0, win: +1, loss: -1) for each pairwise comparison based on whom fared betterMeasure: Composite score incorporating death and the number of days living without mechanical ventilation Time: Day 60
Description: measured each day from day 1 to day 14Measure: Mean evolution of blood gases Time: Day 1 to Day 14
Description: measured each day from day 1 to day 14Measure: Mean evolution of Tidal Volume (ventilator parameters) Time: Day 1 to Day 14
Description: measured each day from day 1 to day 14Measure: Mean evolution of respiratory rate (ventilator parameters) Time: Day 1 to Day 14
Description: measured each day from day 1 to day 14Measure: Mean evolution of Positive Expiratory Pressure (ventilator parameters) Time: Day 1 to Day 14
Description: measured each day from day 1 to day 14Measure: Mean evolution of plateau pressure (ventilator parameters) Time: Day 1 to Day 14
Description: measured each day from day 1 to day 14Measure: Mean evolution of fraction of inspired oxygen (ventilator parameters) Time: Day 1 to Day 14
Description: A higher score indicate a worse outcomeMeasure: Evolution of the Sequential Organ Failure Assessment (SOFA) score and its components by organ Time: Day 1 to Day 28
Description: samples taken on D7 and D14 or the day of discharge from intensive care unit if before D14Measure: Evolution of viral load Time: Day 7, Day 14 or day of ICU discharge if before day 14
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports